Research Paper Volume 13, Issue 12 pp 16341—16352

Figure 5. Ropivacaine inhibits the progression of breast cancer by miR-27b-3p /YAP axis in vitro. (A–D) The MCF-7 and MDA-MB-231 cells were treated with ropivacaine (1 mmol/L) or equal volume saline, or co-treated with ropivacaine (1 mmol/L) and miR-27b-3p inhibitor or YAP overexpression vector. (A and B) The cell viability was analyzed by the MTT assays in the cells. (C and D) The cell apoptosis was measure by flow cytometry analysis in the cells. N = 3, The independent experiments were repeated for three times. Data are presented as mean ± SD. Statistic significant differences were indicated: ^*P < 0.05, ^**P < 0.01, ^***P < 0.001.